Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Chronic obstructive pulmonary disease (COPD)

Clinical research is assessing Mesenchymal Stem Cells (MSCs) in chronic obstructive pulmonary disease (COPD). Investigations are focused on immune pathways and tissue repair to better understand potential roles for MSCs in this respiratory disorder. COPD is a long-term lung disease, commonly linked to smoking and environmental exposure, causing breathlessness, coughing, and reduced quality of life. It remains a leading cause of global morbidity and mortality, with no cure available. MSC studies in COPD are still early-stage, but they contribute to the growing body of research in regenerative medicine for chronic lung conditions.

A placebo-controlled, randomized trial of mesenchymal stem cells in COPD

Daniel J Weiss, et al.
COPD is a devastating disease affecting millions worldwide. As disease pathogenesis includes both chronic pulmonary and systemic inflammation, antiinflammatory effects of systemically administered mesenchymal stem cells (MSCs) may decrease inflammation, resulting in improved lung function and quality of life. The goal of this study was to assess safety and to perform an initial evaluation of the potential efficacy of systemic MSC administration to patients with moderate to severe COPD.
More
Read study

Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: a phase I pilot study

Jesse Armitage, et al.
Hospital admissions for acute COPD exacerbations decreased from 11 events within a year before MSC infusion to six events within a year following infusion, without additional interventions unless required after an exacerbation. Lung function measured 3 weeks after the second infusion did not change significantly compared to pre-infusion levels. These results align with other MSC trials in COPD that also showed no significant improvement in spirometry.
More
Read study

Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels

Daniel J Weiss, et al.
In COPD patients with baseline CRP ≥ 4 mg/L, compared to COPD patients receiving placebo (N = 17), those treated with remestemcel-L (N = 12), demonstrated significant improvements from baseline in forced expiratory volume in one second, forced vital capacity, and six minute walk distance at 120 days with treatment differences evident as early as 10 days after the first infusion. Significant although smaller benefits were also detected in those with CRP levels ≥ 2 or ≥ 3 mg/L.
More
Read study